CRL
NEUTRAL
$169.8
Live
Charles River Laboratories International, Inc. · NYSE
Target $199.33
(+17.4%)
$112.39
52W Range
$228.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 25, 2026
Market cap
$8.38B
P/E
N/A
ROE
-4.2%
Profit margin
-3.6%
Debt/Equity
0.82
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
CRL presents a contradictory profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the company maintains a strong track record of beating earnings estimates and carries an attractive Forward P/E of 13.76, negative profit margins and declining YoY revenue and EPS growth are concerning. The valuation appears discounted (PEG 0.13), but the bearish technical trend and poor health score offset the bullish analyst consensus. Overall, the stock is a value play contingent on a fundamental turnaround that is not yet evident in the data.
Key Strengths
Consistent history of beating quarterly earnings estimates (3/4 last 4 quarters)
Attractive Forward P/E ratio of 13.76 relative to healthcare sector averages
Very low PEG ratio (0.13) suggesting potential undervaluation relative to growth expectations
Manageable Debt/Equity ratio of 0.82
Strong analyst support with a target price of $199.33
Key Risks
Critical financial health weakness indicated by a Piotroski F-Score of 2/9
Negative net profit margin (-3.60%) and negative ROE (-4.23%)
Negative YoY revenue growth (-0.80%) and EPS growth (-10.2%)
Bearish technical trend (0/100) and significant 5-year price decline (-49.5%)
Lack of dividend income or shareholder yield
AI Fair Value Estimate
Based on comprehensive analysis
$184.5
+8.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
33
Weak
65
30
50
20
0
AI Verdict
Speculative Value
Key drivers: Low Forward P/E, Poor Piotroski Score, Negative Growth Metrics, Consistent Earnings Beats
Confidence
85%
Value
65/100
Trades at a significant discount to historical norms and analyst targets, though lacking a Graham Number for defensive baseline.
Positives
- Low Forward P/E (13.76)
- Low PEG (0.13)
Watchpoints
- Price/Book of 2.64 is moderate
Future
30/100
Growth metrics are currently contracting, making the 'Buy' rating dependent on future recovery.
Positives
- Analyst target price suggests ~17% upside
Watchpoints
- Negative YoY Revenue Growth
- Negative YoY EPS Growth
Past
50/100
Strong operational execution in meeting targets, but poor shareholder returns over the long term.
Positives
- Exceptional 25-quarter track record of beating estimates
Watchpoints
- 5-year price performance is deeply negative (-49.5%)
Health
20/100
The Piotroski score indicates severe fundamental weakness in profitability and efficiency.
Positives
- Current Ratio (1.29) is above 1.0
Watchpoints
- Piotroski F-Score of 2/9 is critically low
- Negative Profit Margin
Dividend
0/100
Company does not return capital via dividends.
Positives
No standout positives identified.
Watchpoints
- No dividend yield
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$169.8
Analyst Target
$199.33
Upside/Downside
+17.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CRL and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
Primary
|
-49.5% | -9.5% | +46.7% | -13.8% | +2.4% | -7.7% |
|
BTSG
BrightSpring Health Services, Inc.
Peer
|
+298.8% | +298.8% | +153.9% | +54.4% | +3.9% | +3.0% |
|
ATR
AptarGroup, Inc.
Peer
|
-3.9% | +15.9% | -20.1% | -21.4% | +2.6% | +1.0% |
|
HSIC
Henry Schein, Inc.
Peer
|
+7.6% | -11.6% | +18.5% | +19.3% | -1.5% | +1.9% |
|
CYTK
Cytokinetics, Incorporated
Peer
|
+170.7% | +87.1% | +81.9% | +8.8% | +4.9% | -0.7% |
CRL
Charles River Laboratories International, Inc.
Primary
5Y
-49.5%
3Y
-9.5%
1Y
+46.7%
6M
-13.8%
1M
+2.4%
1W
-7.7%
BTS
BrightSpring Health Services, Inc.
Peer
5Y
+298.8%
3Y
+298.8%
1Y
+153.9%
6M
+54.4%
1M
+3.9%
1W
+3.0%
ATR
AptarGroup, Inc.
Peer
5Y
-3.9%
3Y
+15.9%
1Y
-20.1%
6M
-21.4%
1M
+2.6%
1W
+1.0%
HSI
Henry Schein, Inc.
Peer
5Y
+7.6%
3Y
-11.6%
1Y
+18.5%
6M
+19.3%
1M
-1.5%
1W
+1.9%
CYT
Cytokinetics, Incorporated
Peer
5Y
+170.7%
3Y
+87.1%
1Y
+81.9%
6M
+8.8%
1M
+4.9%
1W
-0.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
13.76
PEG Ratio
0.13
P/B Ratio
2.64
P/S Ratio
2.09
EV/Revenue
2.69
EV/EBITDA
12.35
Market Cap
$8.38B
Profitability
Profit margins and return metrics
Profit Margin
-3.6%
Operating Margin
4.51%
Gross Margin
34.98%
ROE
-4.23%
ROA
4.24%
Growth
Revenue and earnings growth rates
Revenue Growth
-0.8%
Earnings Growth
N/A
Q/Q Revenue Growth
-0.83%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.82
Moderate
Current Ratio
1.29
Good
Quick Ratio
0.82
Poor
Cash/Share
$4.34
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.0B
Gross Margin
31.1%
Op. Margin
9.3%
Net Margin
-27.8%
Total Assets
$7.1B
Liabilities
$3.9B
Equity
$3.2B
Debt/Equity
1.24x
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-18
$2.39
+1.9% surprise
2025-11-05
$2.43
+3.9% surprise
2025-08-06
$3.12
+22.4% surprise
Healthcare Sector Comparison
Comparing CRL against 537 companies in the Healthcare sector
(28 bullish, 159 neutral, 350 bearish)
Return on Equity (ROE)
-4.23%
This Stock
vs
-91.87%
Sector Avg
-95.4%
(Below Avg)
Profit Margin
-3.6%
This Stock
vs
-16.49%
Sector Avg
-78.2%
(Weaker)
Debt to Equity
0.82
This Stock
vs
2.73
Sector Avg
-70.0%
(Less Debt)
Revenue Growth
-0.8%
This Stock
vs
129.42%
Sector Avg
-100.6%
(Slower)
Current Ratio
1.29
This Stock
vs
4.57
Sector Avg
-71.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories...
|
NEUTRAL | $8.38B | - | -4.2% | -3.6% | $169.8 | |
|
BTSG
BrightSpring Health Services, Inc.
|
NEUTRAL | $8.43B | 91.4 | 5.9% | 1.5% | $43.87 | Compare |
|
ATR
AptarGroup, Inc.
|
NEUTRAL | $8.3B | 19.97 | 15.6% | 11.5% | $126.0 | Compare |
|
HSIC
Henry Schein, Inc.
|
BULLISH | $8.65B | 23.04 | 8.7% | 3.0% | $75.34 | Compare |
|
CYTK
Cytokinetics, Incorporated
|
NEUTRAL | $8.06B | - | -% | -% | $65.48 | Compare |
CRL
Charles River...
NEUTRAL
Mkt Cap
$8.4B
P/E
-
ROE
-4.2%
Price
$169.8
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | GIRSHICK BIRGIT | Chief Operating Officer | Gift | 328 | - |
| 2026-03-03 | LAPLUME JOSEPH W | Officer | Purchase | 25 | $4,364 |
| 2026-03-02 | FOSTER JAMES C | Chief Executive Officer | Stock Award | 16,796 | $2,999,934 |
| 2026-01-30 | GIRSHICK BIRGIT | Chief Operating Officer | Stock Award | 9,500 | - |
| 2026-01-30 | LAPLUME JOSEPH W | Officer | Stock Award | 5,456 | - |
| 2026-01-30 | PARISOTTO SHANNON M | Officer | Stock Award | 4,236 | - |
| 2026-01-30 | FOSTER JAMES C | Chief Executive Officer | Stock Award | 39,031 | - |
| 2026-01-30 | KNELL MICHAEL GUNNAR | Chief Financial Officer | Stock Award | 1,668 | - |
| 2026-01-30 | CREAMER VICTORIA L | Officer | Stock Award | 5,006 | - |
| 2026-01-30 | MINTZ MARK | Chief Technology Officer | Stock Award | 1,797 | - |
| 2025-11-06 | KNELL MICHAEL GUNNAR | Chief Financial Officer | Stock Award | 2,926 | $499,995 |
GIRSHICK BIRGIT
Chief Operating Officer
2026-03-04
328 shares
LAPLUME JOSEPH W
Officer
2026-03-03
25 shares
·
$4,364
FOSTER JAMES C
Chief Executive Officer
2026-03-02
16,796 shares
·
$2,999,934
GIRSHICK BIRGIT
Chief Operating Officer
2026-01-30
9,500 shares
LAPLUME JOSEPH W
Officer
2026-01-30
5,456 shares
PARISOTTO SHANNON M
Officer
2026-01-30
4,236 shares
FOSTER JAMES C
Chief Executive Officer
2026-01-30
39,031 shares
KNELL MICHAEL GUNNAR
Chief Financial Officer
2026-01-30
1,668 shares
CREAMER VICTORIA L
Officer
2026-01-30
5,006 shares
MINTZ MARK
Chief Technology Officer
2026-01-30
1,797 shares
KNELL MICHAEL GUNNAR
Chief Financial Officer
2025-11-06
2,926 shares
·
$499,995
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
15 analysts
Barclays
2026-04-14
Overweight
Overweight
JP Morgan
2026-04-13
Neutral
Neutral
UBS
2026-02-25
Neutral
Neutral
TD Cowen
2026-02-20
Buy
Buy
Mizuho
2026-02-20
Neutral
Neutral
Barclays
2026-02-19
Overweight
Overweight
Evercore ISI Group
2026-02-19
Outperform
Outperform
Citigroup
2026-01-16
Buy
Buy
Evercore ISI Group
2026-01-13
Outperform
Outperform
Mizuho
2025-12-18
Neutral
Neutral
Past News Coverage
Recent headlines mentioning CRL from our newsroom.
Newest → oldest
No matching news yet.